Abstract 1008P
Background
TACE is the first choice for patients (pts) with intermediate-stage HCC. Numerous studies have demonstrated the limited survival benefit of TACE alone in pts with stage BCLC B, particularly in tumor beyond up-to-seven criteria. Single immunotherapy agent showed a certain effect for unresectable HCC pts, but still with unsatisfactory. This study was designed to explore the efficacy and safety of sintilimab plus cTACE for HCC with stage BCLC B (or stage CNLC IIa-IIb) beyond up-to-seven criteria.
Methods
This is a single-arm, phase II study(NCT04842565). Eligible HCC pts were treated cTACE and sintilimab (200mg, IV, Q3W). The first sintilimab dose was given after the first cTACE, and then every 3 weeks. The primary objectives were safety and progression-free survival (PFS). Secondary objectives included ORR assessed by both RECIST v1.1 and mRECIST v1.1, overall survival (OS), and disease control rate (DCR).
Results
From Oct 2020 to Feb 2023, 20 pts were enrolled with a median age of 62 years. All pts were BCLC stage B, and 45.0% (9/20) were CNLC IIa stage, 55.0% (11/20) were IIb stage. At median follow-up duration of 9.0 months, the ORR was 30.0%(95% CI: 14.6%-51.9%) per RECIST, and 60% (95%CI: 38.7%-78.1%) per mRECIST. The DCR was 95.0% (95% CI: 76.4%-99.1%) per both RECIST and mRECIST. Median PFS(by both RECIST and mRECIST) was 7.95 months (95% CI: 2.7-NA), and the median OS was not reached. Four pts converted to curative surgical resection. The optimal cut-off value of PLR(platelet-to-lymphocyte ratio) predicted tumor shrinkage was 100. Low PLR were associated with more tumor shrinkage. The most common TRAEs were hypothyroidism (37.5%), elevated aspartate aminotransferase (10.0%), rash(5.0%). Only one patient experienced grade 3 TRAE(myocarditis) and no treatment-related deaths were reported.
Conclusions
Combination of Sintilimab and cTACE showed promising antitumor activity and manageable toxicity in pts with HCC with BCLC stage B (CNLC stage IIa-IIb) beyond up-to-seven criteria. The PLR is promising predictor for tumor shrinkage in HCC. These strategy should be validated in a large randomized controlled trial.
Clinical trial identification
NCT04842565.
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan hospital affiliated to Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18